The pharmacological management of heart failure remains a key component in the treatment of heart failure, offering clinically proven means for reducing morbidity, mortality, and hospitalization rates while enhancing patients’ quality of life. Compared to surgical interventions, pharmacological therapy is less invasive and more easily accessible in certain patient populations. 

Today, we are taking a look at what’s changed recently regarding the pharmacological management of heart failure. We have selected the latest heart failure clinical guidelines featuring guidance on the pharmacological management of heart failure, as well as a rundown of the latest approvals from the U.S. Food and Drug Administration (FDA) related to heart failure. 

First, let’s showcase the latest clinical guidelines that discuss the pharmacological management of heart failure.

Current Heart Failure Guidelines

The two latest U.S.-based clinical guidelines on the management of heart failure, including pharmacological management, are three years old at this point. The ACEP guideline is a revision to a 2007 guideline, and the ACC/AHA/HFSA guideline is a replacement of a 2013 guideline. With 18 and 12 years between the pair of guideline updates, respectively, it may be some time before we see updates to the 2022 guidelines listed below.

With the influx of FDA approvals, as seen further on in this article, it is likely we can expect to see updates at some point, likely sooner than later, considering the ever-growing, large-scale social and financial impact of heart disease in the United States.

Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department with Acute Heart Failure Syndromes

  • American College of Emergency Physicians
  • Published: October 2022

Management of Heart Failure

  • American College of Cardiology / American Heart Association / Heart Failure Society of America
  • Published: April 2022

Additionally, while not a U.S.-based society, the European Society of Cardiology has a slightly more recent guideline on the management of acute and chronic heart failure, which includes guidance on the pharmacological management of heart failure.

Diagnosis and Treatment of Acute and Chronic Heart Failure

  • European Society of Cardiology
  • Published: October 2023
Recent FDA Approvals Related to Heart Failure

The following are heart failure medications recently approved by the FDA that we anticipate being incorporated into future clinical guidelines. These medications include loop diuretics, an nsMRA, and SGLT2 inhibitors.

As clinical trials continue to test the safety and efficacy of additional heart failure management options, we anticipate this list to grow before the next major guideline updates are released from the aforementioned societies.

Lasix ONYU (furosemide injection)

  • SQ Innovation, Inc
  • Approved: October 8, 2025
  • Lasix ONYU is a loop diuretic indicated for the treatment of edema in adult patients with chronic heart failure. 

Enbumyst (bumetanide nasal spray)

  • Corstasis Therapeutics
  • Approved: September 15, 2025
  • Enbumyst is a loop diuretic indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including nephrotic syndrome in adults.

Kerendia (finerone)

  • Bayer
  • Approved: July 14, 2025
  • Kerendia is a non-steroidal mineralocorticoid receptor antagonist (nsMRA) indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adult patients with heart failure with LVEF ≥40%. Kerendia is also indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with CKD associated with T2DM.

Furoscix (furosemide injection)

  • scPharmaceuticals
  • Approved: August 12, 2024
  • Furoscix is a loop diuretic indicated for the treatment of edema in adult patients with chronic heart failure or chronic kidney disease, including the nephrotic syndrome.

Inpefa (sotagliflozin)

  • Lexicon Pharmaceuticals
  • Approved: May 26, 2023
  • Inpefa is a sodium-glucose contransporter 2 inhibitor indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or T2DM, CKD, and other cardiovascular risk factors.

Farxiga (dapagliflozin)

  • AstraZeneca
  • Approved: May 9, 2023
  • Farxiga is a sodium-glucose cotransporter 2 inhibitor indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression; To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure; To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors; and as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.

Sign up for alerts to keep up with the latest guidelines and insights.

Copyright © 2025 Guideline Central, all rights reserved.